Triazolopyridazines as tyrosine kinase modulators

The invention is directed to triazolopyridazine compounds of Formula (I): where R, R, R, R, R, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met i...

Full description

Saved in:
Bibliographic Details
Main Authors CONNORS, RICHARD W, MARONEY, ANNA C, SECHLER, JAN L, CUMMINGS, MAXWELL D, LU, TIANBAO, TRAVINS, JEREMY M, HUFNAGEL, HEATHER RAE, ALEXANDER, RICHARD, MARKOTAN, THOMAS P, LEONARD, KRISTI A, GALEMMO, ROBERT A, TUMAN, ROBERT W, JOHNSON, DANA L, KHALIL, EHAB
Format Patent
LanguageEnglish
Published 30.08.2012
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention is directed to triazolopyridazine compounds of Formula (I): where R, R, R, R, R, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
Bibliography:Application Number: AU20060331912